BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 31, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2018

View Archived Issues

Virpax signs license agreement to use LipoCure's liposome drug delivery technology

Read More

Microbiotica and Genentech enter strategic collaboration for IBD

Read More

FDA grants rare pediatric disease designation to CLR-131 for the treatment of rhabdomyosarcoma

Read More

Intra-Cellular initiates rolling submission of NDA for lumateperone

Read More

Moleculin Biotech enters agreement to develop formulation for its STAT3 inhibitor

Read More

Alkermes receives payment from Biogen related to BIIB-098 program

Read More

Effects on gut microbiome seen with Blautix in irritable bowel syndrome patients

Read More

S1P regulation key for bone quality and may constitute a therapeutic target in osteoporosis

Read More

Shandong Luoxin Pharmacy Group, Luoxin Biotechnology Shanghai Co. patent BRD4/1/2 inhibitors

Read More

Jiangsu Chia Tai Tianqing Pharmaceutical Group, Medshine Discovery identify HBV cccDNA inhibitors

Read More

New RORC modulators divulged by Bristol-Myers Squibb

Read More

Weishang Shanghai Bio-Pharmaceutical discovers mutant EGFR inhibitors

Read More

Merck & Co. synthesizes new FXIIa inhibitors

Read More

Dosing begins in phase II expansion portion of monotherapy trial of eFT-508 in non-GCB DLBCL

Read More

ROR-1-targeting cirmtuzumab inhibits stemness signatures in phase I trial in CLL patients

Read More

First healthy volunteers enrolled in phase I study of BTRX-335140

Read More

Positive results presented from ongoing phase I trial of PTI-801 in patients with CF

Read More

4D pharma and MSD collaborate to study Keytruda and MRx-0518 combination in solid tumors

Read More

FDA grants orphan drug designation to TransCon PTH

Read More

EMA grants PRIME designation for dilanubicel

Read More

Athersys expands its collaboration with Healios

Read More

Phase II results presented for TAK-954 in patients with enteral feeding intolerance

Read More

GlaxoSmithKline initiates phase I study of GSK-3858279

Read More

Enrollment ongoing in phase III study of pertuzumab and trastuzumab fixed-dose combination

Read More

Selinexor liposarcoma trial advances after improvement seen in progression-free survival

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 31, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing